| Source: |
| Type: |
| ADAM17 (A Disintegrin and Metalloprotease 17), also known as TACE (Tumor Necrosis Factor-α Converting Enzyme), is a membrane-anchored protease. – It is best known for cleaving and releasing the extracellular domains (ectodomains) of various cell surface proteins, a process called “ectodomain shedding.” Numerous studies have documented increased ADAM17 expression in several cancers, such as breast, lung, colon, and pancreatic cancers. – Upregulation often correlates with enhanced release of growth factors (e.g., EGF family ligands) and cytokines that may drive tumor growth and modify the tumor microenvironment. – Higher levels of ADAM17 have been linked with more aggressive tumor characteristics, including increased invasiveness, metastasis, and resistance to certain therapies. – In cancers such as breast and lung, elevated ADAM17 expression is often associated with poor clinical prognosis. |
| 1091- | GA, | Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | HTB-35 |
| 3047- | SK, | Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:994 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid